METLIFE GROUP INC. Discloses $19,000 in Lobbying Efforts
In a recent Lobbying Disclosure Act filing, METLIFE GROUP INC. (formerly known as Metropolitan Life) revealed $19,000 spent on lobbying during the fourth quarter of 2024.
Focus Areas in Lobbying
The lobbying efforts centered on crucial topics such as:
- Insurance law reforms
- Financial services and securities law reforms
For further details about corporate lobbying activities, visit Quiver Quantitative.
MET’s Congressional Stock Transactions
Members of Congress executed one transaction involving $MET stock in the past six months. This included zero purchases and one sale.
To observe the details of congressional trading, refer to Quiver Quantitative’s congressional trading dashboard.
Insider Trading Trends at MET
Insiders of MET have also engaged in trading, with two transactions recorded in the past six months, both being sales.
For tracking insider trades, explore Quiver Quantitative’s insider trading dashboard.
Activity Among Hedge Funds
In the latest quarter, 559 institutional investors adjusted their holdings in MET stock. Notably, 564 investors reduced their positions.
Here are significant changes among large investors:
- PRICE T ROWE ASSOCIATES INC /MD/ decreased their portfolio by 13,728,972 shares (-42.7%) in Q3 2024.
- VIKING GLOBAL INVESTORS LP increased their holdings by 4,487,602 shares (+inf%) in Q3 2024.
- WELLINGTON MANAGEMENT GROUP LLP cut back by 3,106,583 shares (-14.3%) in Q3 2024.
- BALYASNY ASSET MANAGEMENT L.P. boosted their portfolio by 1,924,209 shares (+3037.6%) in Q3 2024.
- BLACKROCK, INC. added 1,873,883 shares (+3.9%) to their holdings in Q3 2024.
- DODGE & COX removed 1,696,700 shares (-3.0%) from their portfolio in Q3 2024.
- GOLDMAN SACHS GROUP INC decreased their share count by 1,378,318 shares (-35.1%) in Q3 2024.
To keep track of hedge fund investments, check out Quiver Quantitative’s institutional holdings dashboard.
This article is not financial advice. For more details, see Quiver Quantitative’s disclaimers.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
